PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 4 explicitly reviewed source snapshots.
4 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 4 explicitly reviewed source snapshots.
4 reviewed citations
- PubMed · 40550229 · Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. ↗
- PubMed · 40550231 · Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. ↗
- PubMed · 42532079 · Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. ↗
- PubMed · 42532080 · Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. ↗
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 2 from 5 explicitly reviewed source snapshots.
5 reviewed citations
- PubMed · 40550229 · Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. ↗
- PubMed · 40550231 · Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. ↗
- PubMed · 42532079 · Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. ↗
- PubMed · 42532080 · Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. ↗
- PubMed · 42443140 · Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide. ↗
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 3 explicitly reviewed source snapshots.
3 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 2 from 6 explicitly reviewed source snapshots.
6 reviewed citations
- PubMed · 34798060 · Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial ↗
- PubMed · 40544433 · Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. ↗
- PubMed · 40544432 · Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. ↗
- PubMed · 42251860 · Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. ↗
- PubMed · 42251859 · Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. ↗
- PubMed · 42251856 · Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. ↗
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 2 from 3 explicitly reviewed source snapshots.
3 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 3 explicitly reviewed source snapshots.
3 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 3 explicitly reviewed source snapshots.
3 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 3 explicitly reviewed source snapshots.
3 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 3 explicitly reviewed source snapshots.
3 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 2 from 4 explicitly reviewed source snapshots.
4 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 3 explicitly reviewed source snapshots.
3 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 4 explicitly reviewed source snapshots.
4 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 3 explicitly reviewed source snapshots.
3 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 1 explicitly reviewed source snapshot.
1 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 3 explicitly reviewed source snapshots.
3 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 3 explicitly reviewed source snapshots.
3 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 2 from 3 explicitly reviewed source snapshots.
3 reviewed citations
- PubMed · 37366315 · Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial ↗
- PubMed · 37385280 · Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA ↗
- PubMed · 42250575 · Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. ↗
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 2 from 4 explicitly reviewed source snapshots.
4 reviewed citations
PeptideScanner published September 15, 2026
PeptideScanner published bounded review version 1 from 3 explicitly reviewed source snapshots.
3 reviewed citations
PeptideScanner published September 14, 2026
PeptideScanner published bounded review version 1 from 3 explicitly reviewed source snapshots.
3 reviewed citations
PeptideScanner published August 19, 2026
PeptideScanner published bounded review version 1 from 1 explicitly reviewed source snapshot.
1 reviewed citations
PeptideScanner published August 19, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published August 19, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published August 19, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published August 19, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published August 19, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
- PubMed · 33137293 · Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials ↗
- PubMed · 36356613 · Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period ↗
PeptideScanner published August 19, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published August 19, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published August 19, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published August 19, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published August 18, 2026
PeptideScanner published bounded review version 1 from 3 explicitly reviewed source snapshots.
3 reviewed citations
PeptideScanner published August 18, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
PeptideScanner published August 18, 2026
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations